Ad
related to: publicly traded crispr companies
Search results
Results From The WOW.Com Content Network
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing , whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods [ vague ] .
The company was founded in 2017 [3] by Jennifer Doudna, Janice Chen, and Lucas Harrington of the University of California, Berkeley, and Trevor Martin of Stanford University. [4] Mammoth signed agreements in December 2019 and January 2020 with Horizon Discovery to combine Mammoth's intellectual property in CRISPR with Horizon's expertise in ...
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise ...
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. [4]
Editas works with two different CRISPR nucleases, Cas9 and Cas12a. [29] EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, which is currently in clinical trials. EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 ...
The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company is listed on the Nasdaq Global Select Market under the ticker symbol "AMGN", as well as a component of ...
The company's beginnings were profiled by Barry Werth in the 1994 book The Billion-Dollar Molecule. [4] His 2014 book, The Antidote: Inside the World of New Pharma, chronicled the company's subsequent development over the next two decades. [6] By 2004, its product pipeline focused on viral infections, inflammatory and autoimmune disorders, and ...